Drug class
SARS-CoV-2 main protease (3CLpro/Mpro) inhibitor; antiviral component of Paxlovid
Mechanism of action
Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.
General use cases
- In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
